Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 15/100

Failure Rate

0.0%

0 terminated/withdrawn out of 6 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

33%

2 trials in Phase 3/4

Results Transparency

50%

2 of 4 completed trials have results

Key Signals

1 recruiting2 with results

Enrollment Performance

Analytics

Phase 3

2(50.0%)

Phase 2

1(25.0%)

Phase 1

1(25.0%)

4Total

Phase 3(2)

Phase 2(1)

Phase 1(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (6)

Showing 6 of 6 trials

NCT07465718Phase 3Not Yet Recruiting

Trientine Tetrahydrochloride Administered Once a Day for the First Line Treatment of Wilson's Disease Patients.

Role: lead

NCT07010575Phase 2Completed

Patient Preference Study: Standard of Care Versus Once-daily Trientine Tetrahydrochloride

Role: lead

NCT05783687Completed

Real World Evidence Study in Subjects With Wilson's Disease

Role: lead

NCT06128954Phase 1Completed

Study Comparing Once Daily Dose of 900mg of TETA 4HCL Against Cuprior® (450mg Trientine Base, Twice Daily).

Role: lead

NCT05239858Recruiting

International Wilson's Disease Patient Registry (iWilson Registry)

Role: lead

NCT03539952Phase 3Completed

Trientine Tetrahydrochloride (TETA 4HCL) for the Treatment of Wilson's Disease

Role: lead

All 6 trials loaded